S-Adenosyl-Methionine improves depression in patients with Parkinson's disease in an open-label clinical trial.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/11104210
Conclusion of this study
One patient experienced mild nausea, and another two patients developed mild diarrhea, which resolved spontaneously. The mean HDS score before treatment was 27.09 +/- 6.04 (mean +/- standard deviation) and was 9.55 +/- 7.29 after SAM treatment (p < 0.0001). Although uncontrolled and preliminary, this study suggests that SAM is well tolerated and may be a safe and effective alternative to the antidepressant agents currently used in patients with Parkinson's disease.
Supplements analyzed in this study
Health conditions analyzed in this study
Functions related to this study
Body systems related to this study